J. Henri Bayle
Chief Tech/Sci/R&D Officer chez BELLICUM PHARMACEUTICALS, INC.
Profil
J.
Henri Bayle is currently working as the Vice President-Research at Bellicum Pharmaceuticals, Inc. He completed his undergraduate degree from the University of Alberta and his doctorate from Princeton University.
Postes actifs de J. Henri Bayle
| Sociétés | Poste | Début |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
Formation de J. Henri Bayle
| University of Alberta | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
